drug

Sodium Benzoate Plus N-Acetylcysteine

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Pakistan Institute of Living and Learning
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

1
Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.
NCT03510741Phase 2Completed

KOLs & investigators

1
Prof Imran B Chaudhry, MDKOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Pakistan Institute of Living and Learning
company
trial
Sodium Benzoate and/or N-Acetylcysteine Added to TAU in Patients With Early Schizophrenia Spectrum Disorder.
PHASE2
trial
indication
Schizophrenia
indication
Inflammation
indication
Schizophreniform Disorders
indication
Schizophrenia
indication
KOL
Prof Imran B Chaudhry, MD
KOL score 5
person